Inactive Instrument

IGI Laboratories, Inc. Nyse

Equities

US4495751095

End-of-day quote Nyse Other stock markets
- ^USD	-

2022	Teligent, Inc. Went Out of Business	CI
2022	Second Amended Liquidation Plan Approved for Teligent, Inc.	CI

IGI Laboratories : To Present At 33rd Annual J.P. Morgan Healthcare Conference On January 15, 2015

January 08, 2015 at 08:01 am EST

BUENA, N.J., Jan. 8, 2015 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based specialty generic pharmaceutical company, will be presenting at the 33(RD) Annual J.P. Morgan Healthcare Conference. The Conference will take place on January 12-15, 2015 at the Westin St. Francis Hotel in San Francisco, California.

http://photos.prnewswire.com/prnvar/20130827/MM70487LOGO

Jason Grenfell-Gardner, CEO and President and Jenniffer Collins, Chief Financial Officer of IGI Laboratories, Inc. will present on Thursday January 15, 2015 at 10:30 a.m. PT.

The presentation will be webcast and will be accessible online on the investors section of the Company's website at http://www.igilabs.com. A replay will be available for 90 days.

About IGI Laboratories, Inc.
IGI Laboratories is a specialty generic drug development and manufacturing company. Our mission is to be a leading player in the specialty generic prescription drug market.

Logo - http://photos.prnewswire.com/prnh/20130827/MM70487LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/igi-laboratories-to-present-at-33rd-annual-jp-morgan-healthcare-conference-on-january-15-2015-300017530.html

SOURCE IGI Laboratories, Inc.

Latest news about IGI Laboratories, Inc.

Teligent, Inc. Went Out of Business	22-07-26	CI
Second Amended Liquidation Plan Approved for Teligent, Inc.	22-07-15	CI
Second Motion for Exclusivity Period Extension Approved For Teligent, Inc.	22-05-25	CI
Second Amended Joint Liquidation Plan Filed by Teligent, Inc.	22-05-24	CI
First Amended Disclosure Statement Approved for Teligent, Inc.	22-04-29	CI
First Amended Joint Liquidation Plan and Disclosure Statement Filed by Teligent, Inc.	22-04-27	CI
Joint Liquidation Plan and Disclosure Statement Filed by Teligent, Inc.	22-04-08	CI
First Motion for Exclusivity Period Extension Approved For Teligent, Inc.	22-02-28	CI
Motion for Case Conversion Filed by Teligent, Inc.	22-02-22	CI
First Motion for Exclusivity Period Extension Filed by Teligent, Inc.	22-02-09	CI
Hikma Pharmaceuticals Closes $46 Million Purchase of Teligent's Canadian Assets	22-02-03	MT
Pharmaceutical Associates, Inc. completed the acquisition of Generic and Branded US Marketing Authorizations of Teligent, Inc. (OTCPK:TLGT.Q).	22-02-02	CI
Hikma Pharmaceuticals PLC completed the acquisition of Canadian assets of Teligent Inc from Teligent, Inc. (OTCPK:TLGT.Q).	22-02-02	CI
Motion for Asset Sale Approved for Teligent, Inc.	22-01-19	CI
Motion for Asset Sale Approved for Teligent, Inc.	22-01-19	CI
Motion for Asset Sale Approved for Teligent, Inc.	22-01-18	CI
London Shares to Open Higher as Traders Focus On Key Data	22-01-17	DJ
Hikma Pharmaceuticals to Enter Canadian Market With $46 Million Asset Acquisition	22-01-17	MT
Asset Purchase Agreement Filed by Teligent, Inc.	22-01-16	CI
Asset Purchase Agreement Filed by Teligent, Inc.	22-01-16	CI
Asset Purchase Agreement Filed by Teligent, Inc.	22-01-16	CI
Hikma Pharmaceuticals PLC agreed to acquire Canadian assets of Teligent Inc. from Teligent, Inc. (OTCPK:TLGT.Q) for $45.7 million.	22-01-16	CI
Notice of Selection of Successful Filed for Teligent, Inc.	22-01-14	CI
Notice of Selection of Successful Filed for Teligent, Inc.	22-01-13	CI
Notice of Selection of Successful Filed for Teligent, Inc.	22-01-13	CI

Chart IGI Laboratories, Inc.

Duration

Period

More charts

Company Profile

Teligent, Inc. is a generic pharmaceutical company. The Company is focused on the development, manufacturing and marketing of a portfolio of generic pharmaceutical products under its own label and private label for other pharmaceutical companies in topical, injectable, complex and other dosage forms. It also provides contract development and manufacturing services to the prescription and over-the-counter (OTC) pharmaceutical and cosmetic markets. Under the Company's own label, it markets and sells generic topical, and generic and branded generic injectable pharmaceutical products in the United States. In the United States, the Company markets approximately 37 generic topical pharmaceutical products and one branded injectable pharmaceutical product. The Company's portfolio of hospital-based sterile injectable products, including cephalosporins, Cefotan (Cefotetan for Injection), Fortaz (Ceftazidime) and Zinacef (Cefuroxime Sodium).

Sector

More about the company